Today, Governor Ron DeSantis issued Executive Order 22-164 to drive transparency in prescription costs for Floridians.
This order will ensure reforms are in place to hold Pharmacy Benefits Managers (PBMs) accountable when managing prescription drug benefits for insurance companies. Governor DeSantis remains committed to finding ways to deliver safe, affordable prescription drugs to Floridians.
“Florida continues to lead the nation in ensuring accountability in the health care industry and in introducing reforms to combat rising prescriptions costs,” said Governor Ron DeSantis. “This executive order requires accountability and transparency for pharmaceutical middlemen when doing business with the state, thereby reducing the upward pressure on prescription drug costs.”
“For far too long leaders have chosen the path of inaction, rather than action, and fallen victim to a pharmaceutical system driven by drug companies rather than consumers,” said Agency for Health Care Administration Secretary Simone Marstiller. “Fortunately, Governor DeSantis leads with principle, always putting Floridians first and today’s actions will further this commitment by providing insight into the FDA’s review process and all agency health care contracts through the end of the decade.”
In the news: Biden Signs Executive Order On Abortion Calling SCOTUS Decision “Extreme” And “Totally Wrong”
The Executive Order directs all executive agencies to include provisions in all future contracts and solicitations with these PBMs, services that include the following:
- Prohibit spread pricing for all PBMs;
- Prohibit reimbursement clawbacks for all PBMs;
- Directs agencies to include data transparency and reporting requirements, including a review of all rebates, payments, and relationships between pharmacies, insurers, and manufacturers; and
- Directs all impacted agencies to amend all contracts to the extent feasible with these same provisions.
Florida has taken previous actions to lower the costs of prescription drugs for residents that continue to be stalled by the federal government.
The state’s landmark Canadian Prescription Drug Importation program has been under review by the FDA for nearly 600 days.
Governor DeSantis also announced today that the Agency for Health Care Administration (AHCA) filed a Freedom of Information Act (FOIA) request to gain insight into the status of their proposal to lower drug costs for Floridians.
The FDA must provide transparency on their review process, and Florida will hold them accountable to ensure they are not putting politics over patients.
Visit Tampafp.com for Politics, Tampa Area Local News, Sports, and National Headlines. Support journalism by clicking here to our GiveSendGo or sign up for our free newsletter by clicking here.
Android Users, Click Here To Download The Free Press App And Never Miss A Story. Follow Us On Facebook Here Or Twitter Here.
Copyright 2022 The Free Press, LLC, tampafp.com. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Login To Facebook From Your Browser To Leave A Comment